Medindia

X

Adult COPD or asthma could be effectively treated with Xopenex

by Medindia Content Team on  February 11, 2003 at 5:07 PM Drug News   - G J E 4
Adult COPD or asthma could be effectively treated with Xopenex
COPD - Chronic Obstructive Pulmonary Disease - including chronic bronchitis and emphysema, is characterized by breathing difficulty due to partial blockage of the bronchial tubes. Asthma is a chronic lung disease caused by inflammation of the lower airways resulting in episodes of airflow obstruction, which has been found to be the fourth most common cause of death and affects nearly 16 million people in the United States. According to the American Lung Association, it is the most common childhood illness and affects approximately 8.6 million children under the age of 18.
Advertisement

A new study conducted at the Halifax Regional Hospital in South Boston, suggested Xopenex as a viable first-line therapy for hospitalized adult COPD or asthma patients. Lead author of the study, Terrance Truitt said that Xopenex is safe in a hospital setting, and is an effective alternative to racemic albuterol in treating the bronchial smooth muscle spasm associated with diseases such as COPD and asthma. The study involved the comparison of the treatment of 231 patients with similar background and disease conditions over two separate six-month periods. The first group had been treated with the previous standard treatment, the second group with Xopenex. It was found that the subjects showed significant symptom improvement and a change in the frequency of nebulizer treatments - in intervals of 6 to 8 hours. This change was achieved with a 1.25 mg dose of Xopenex. In addition, the Xopenex group needed only 2.0 +/- 2.6 days of ipratropium bromide treatments. Patients receiving Xopenex were found to require significantly less nebulizer therapy and less adjuvant respiratory therapy, according to the study.

Advertisement
Xopenex is being marketed as a nebulizer at dosage strengths of 0.31 mg and 0.63 mg for pediatric patients and as 0.63 mg and 1.25 mg for patients 12 years of age and older. Xopenex brand levalbuterol HCl inhalation solution is indicated for the treatment or prevention of bronchospasm in patients 6 years and older with reversible obstructive airway disease, such as asthma.

Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions
I NEED BUY XOPENEX FOR MY CHILD HE HAS FIBROSIS PULMONAR IN SPANISH NAME,BUT HERE NOT SALE THIS DRUGS
guest Friday, October 12, 2007

You May Also Like

Advertisement
View All